Press Releases AllCelleron TherapeuticsEvents & PresentationsPress ReleasesRelevant Publications Celleron Therapeutics announces successful completion of Phase 1b Clinical Trial January 14, 2019 Celleron Therapeutics Announces the appointment of Simon Cook as Clinical Research Director January 14, 2019 2018 Professor David Kerr Presents at the 3rd, World Precision Medicine (China) Summit in Shanghai. December 20, 2018 Dr Shunsheng Zheng appointed as Business Development Director November 12, 2018 Dr Hao Zhang appointed as Vice President Business Development and Commercialisation October 18, 2018 2018 Shenzhen Pingshan International Biopharmaceutical Industry Innovation & Development Summit October 1, 2018 Celleron Therapeutics Begins a Pioneering Combination Therapy Approach to Treating Colorectal Cancer August 20, 2018 Prof David Kerr’s trip to China June 13, 2018 Celleron Therapeutics announces Initiation of Patient Enrolment into the Expansion Cohort of its CXD101 Phase 1 Clinical Trial June 11, 2018 Celleron Therapeutics Selects Syneos Health to Conduct Clinical Trial Programme for CXD101 on MAY 1, 2018 May 1, 2018 Celleron Therapeutics announces MHRA Clinical Trial Authorisation for CXD101 in Microsatellite-Stable Colorectal Cancer March 26, 2018 Celleron Therapeutics appoints Bill Fleming as its Chief Financial Officer February 9, 2018 Celleron Therapeutics announces EMA COMP Orphan Drug designation for CXD101 in peripheral T-cell lymphoma December 6, 2017 Celleron Therapeutics announces Licensing and Co-Development Agreement with Nuance Biotech for China and South Africa November 13, 2017 Dr Chris Towler joins the Board of Celleron Therapeutics July 24, 2017 CXD101 presented at 3rd Shanghai International Forum July 3, 2017 Dr. Doug Manion joins Board of Celleron Therapeutics June 1, 2017 CXD101 update presented at Inaugural Meeting of Oxford Centre for Cancer Gene Research April 18, 2017 Why Don’t Immune Checkpoint Inhibitors Work in Colorectal Cancer? April 10, 2017 Celleron Therapeutics announces completion of a new funding round with international investors January 31, 2017 TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism December 10, 2016 « Previous 1 2 3 4 Next »
